CN117462626B

CN117462626B - Traditional Chinese medicine composition for treating skin injury caused by rash

Info

Publication number: CN117462626B
Application number: CN202311664721.8A
Authority: CN
Inventors: 梁博文; 李华; 李波; 赵丽萍; 罗敬月; 鲜馥阳
Original assignee: Beijing Chest Hospital; Beijing Tuberculosis and Thoracic Tumor Research Institute
Current assignee: Beijing Chest Hospital; Beijing Tuberculosis and Thoracic Tumor Research Institute
Filing date: 2023-12-06
Publication date: 2024-07-09
Anticipated expiration: 2043-12-06

Abstract

The invention belongs to the technical field of medicines, and in particular relates to a traditional Chinese medicine composition for treating skin rash and skin injury caused by the rash, wherein the rash is skin rash which is generated by diagnosing lung cancer and receiving EGFRIs medicine treatment, the skin injury reaches skin erosion, exudation, hypertrophy and moss which are generated by rash of 2 minutes or more, and the rash is mainly caused by insufficient endowment of a patient, inward invasion of wind, heat and damp evil, and external and internal combination of evil with special toxin of a medicine. The traditional Chinese medicine composition provided by the invention comprises the following components: 30-50 parts of honeysuckle, 30-50 parts of purslane, 30-50 parts of radix sophorae flavescentis, 30-50 parts of cortex dictamni, 20-40 parts of radix scutellariae, 20-40 parts of lithospermum, 20-40 parts of radix sileris, 10-20 parts of dried alum, 20-40 parts of bletilla striata and 20-50 parts of radix sanguisorbae. Clinical practice shows that the honeysuckle flower and astragalus root lotion has good clinical effect on treating the severe rash.

Description

Traditional Chinese medicine composition for treating skin injury caused by rash

Technical Field

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating rash and skin injury caused by the rash.

Background

Lung cancer is the malignant tumor with highest global morbidity and mortality, and is classified into two major classes, namely small cell lung cancer and non-small cell lung cancer (NSCLC) according to the histopathological classification. Malignant tumors in Chinese residents are first in the death rate of various diseases, the incidence rate and death rate of lung cancer are the first, the total number of new lung cancer cases in China every year is 73.3 ten thousand, the death number is about 61 ten thousand, non-small cell lung cancer (NSCLC) accounts for about 80-85% of the total number, squamous cell carcinoma (squamous cell carcinoma), adenocarcinoma and large cell carcinoma, about 75% of patients have been found to be locally advanced or metastatic diseases, the survival rate of 5 years is very low, the survival rate of squamous cell lung cancer accounts for 29% of lung cancer, and the lung cancer also starts from large bronchi, but the growth is slower. The size of these tumors varies in diagnosis. Adenocarcinomas are the most common subtype of NSCLC, accounting for 32% of lung cancer, which is a form that begins near the gas exchange surface of the lung. Most cases of adenocarcinoma are associated with smoking, however, in humans who never smoke, adenocarcinoma is the most common form of lung cancer. Subtypes of adenocarcinoma, bronchioloalveolar carcinoma, are more common in female non-smokers and may have different responses to treatment. Large cell carcinoma is a rapidly growing form, 9% of lung cancer, which grows near the surface of the lung. Small cell lung cancer (SCLC, also known as "oat cell carcinoma") is a rare form of lung cancer. It tends to start with a large breathing tube and grow rapidly to become very large. The "oat" cells contain dense neurosecretory particles, which lead to this endocrine/paraneoplastic syndrome combination. It is initially more sensitive to chemotherapy, but eventually leads to a poor prognosis and is often metastatic in appearance.

The EGF receptor inhibitor (EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS, EGFRIs) is an important means for treating lung cancer at present due to the outstanding curative effect in the treatment of malignant tumors such as non-small cell lung cancer, colorectal cancer and the like, and has more clinical application at present, but the accompanying adverse reaction brings great trouble to patients receiving treatment. EGFR directs proliferation, adhesion, migration, differentiation and apoptosis of cells, and is closely related to the formation and deterioration of tumor cells such as lung cancer, breast cancer, and prostate cancer. The EGFRIs-related rash with the earliest occurrence and highest occurrence rate in EGFRIs-related skin adverse reactions has great influence on various aspects of image, social contact, life quality and the like of patients, and even causes that part of patients have to stop receiving EGFRIs treatment, thereby influencing the survival time of the patients. It is currently believed that EGFRIs-related rash occurs in association with mechanisms such as cytokine-mediated inflammatory responses, and thus clinical guidelines recommend the use of antibiotics and hormones to treat rash, but the efficacy is unsatisfactory and antibiotics and hormones are associated with no minor side effects.

EGFRIs related rashes are classified as "toxic drugs" in traditional Chinese medicine. The "the theory of disease sources, sore diseases, sore on the head and face and body" considers that the lung governs qi and is in the fur; the spleen governs the muscles. Skin striae are broken due to qi deficiency, which is the cause of rheumatism; internal heat causes spleen qi to warm and spleen air temperature causes muscle to generate heat. The heat and dampness are combined to promote the generation of sores on the head, face and body, which means that the rash is located in the lung and related to the spleen and stomach, and wind, damp and heat are three pathological factors. In combination with the characteristics of the literature and clinical manifestations, the rash caused by EGFRIs is mostly caused by insufficient endowment of the body of the patient, invasion of wind, heat and damp evil, special toxin of the sensitive medicine and internal and external evil. The traditional Chinese medicine intervention can obviously relieve EGFRIs related skin toxic reaction grades, obviously relieve traditional Chinese medicine symptoms of a patient, improve the life quality of the patient, and does not influence the anti-tumor curative effect of EGFRIs.

In Chinese patent CN107617010B, a traditional Chinese medicine composition for external use for treating rash is disclosed, and a preparation method and application thereof, wherein the traditional Chinese medicine composition comprises the following traditional Chinese medicines: the prescription is used for treating EGFRIs related rash, but other symptoms of EGFRIs related rash, such as itching, bleeding, pain and the like, which appear in the repairing process, are ignored, so that broad-spectrum treatment cannot be realized. As another example, in chinese patent CN101810799B, a traditional Chinese medicine composition for treating eruption and a preparation method thereof are disclosed, the traditional Chinese medicine composition is composed of the following traditional Chinese medicines: herba schizonepetae, radix sileris, fructus forsythiae, dandelion, mint, fructus arctii, periostracum cicadae, fermented soybean, radix puerariae, radix bupleuri, folium mori, chrysanthemum, gypsum, rhizoma anemarrhenae, radix trichosanthis, lophatherum gracile, radix scutellariae, cortex dictamni, radix sophorae flavescentis, cortex fraxini, radix rehmanniae, radix scrophulariae, cortex moutan, lithospermum, honeysuckle, bunge corydalis herb, indigo naturalis, herba houttuyniae, purslane, pulsatilla chinensis, rhizoma smilacis glabrae, cortex lycii radicis, semen pruni, rheum officinale, angelica sinensis, radix paeoniae alba, radix astragali, gardenia, selfheal, reed rhizome and the like are complex in formula, and the problems of itching and the like in the repairing process are also ignored. The invention is based on the traditional Chinese medicine formula disclosed in Chinese patent CN107617010B, and the traditional Chinese medicine composition is added on the basis of the traditional Chinese medicine formula, so that the traditional Chinese medicine composition not only can treat EGFRIs related rash, but also can take care of the problems in repairing, and has reasonable formula compatibility and obvious effect.

The theory of external treatment, i.e. the theory of internal treatment, the recipe of external treatment, i.e. the recipe of internal treatment, is called "Li yue parallel text". As can be seen from the above, the external treatment is based on the theory of internal treatment, and the external treatment can also have the efficacy of internal treatment. For EGFR-TKIs related rash, the external medicine can directly permeate skin and skin striae and striae of the body surface, and can reach meridians and collaterals to reach viscera and disease places, thereby regulating qi and blood and yin-yang balance of the organism to exert curative effect.

Disclosure of Invention

In a first aspect, the invention provides a traditional Chinese medicine composition for treating skin rash and skin injury caused by the rash, wherein the rash is skin rash which is caused by diagnosing lung cancer and receiving EGFRIs medicine treatment, the skin injury reaches skin erosion, exudation, hypertrophy and lichenification which are caused by rash of 2 minutes or more, the rash is mainly caused by insufficient endowment of a patient, invasion of wind, heat and damp evil, and special toxin of a sensitive medicine is additionally caused by internal and external evil, and the traditional Chinese medicine composition is prepared from the following traditional Chinese medicines in parts by weight: 30-50 parts of honeysuckle, 30-50 parts of purslane, 30-50 parts of radix sophorae flavescentis, 30-50 parts of cortex dictamni, 20-40 parts of radix scutellariae, 20-40 parts of lithospermum, 20-40 parts of radix sileris, 10-20 parts of dried alum, 20-40 parts of bletilla striata and 20-50 parts of radix sanguisorbae.

The scoring criteria for skin lesions are shown in the following table:

Further, the traditional Chinese medicine composition is prepared from the following traditional Chinese medicinal materials in parts by weight: 35-45 parts of honeysuckle, 35-45 parts of purslane, 35-45 parts of radix sophorae flavescentis, 35-45 parts of cortex dictamni, 25-35 parts of radix scutellariae, 25-35 parts of lithospermum, 25-35 parts of radix sileris, 10-15 parts of dried alum, 25-35 parts of bletilla striata and 25-40 parts of radix sanguisorbae.

Further, the traditional Chinese medicine composition is prepared from the following traditional Chinese medicinal materials in parts by weight: 40 parts of honeysuckle, 40 parts of purslane, 40 parts of radix sophorae flavescentis, 40 parts of cortex dictamni, 30 parts of radix scutellariae, 30 parts of lithospermum, 30 parts of radix saposhnikoviae, 15 parts of dried alum, 30 parts of bletilla striata and 40 parts of radix sanguisorbae.

Further, the lung cancer may be classified into small cell lung cancer and non-small cell lung cancer.

In a second aspect, the invention provides a traditional Chinese medicine composition preparation for treating skin rash and skin injury caused by the skin rash, wherein the skin rash is skin erosion, exudation, hypertrophy and lichenification of skin rash which occur in lung cancer diagnosis and EGFRIs drug treatment, the skin injury reaches 2 minutes or more, the traditional Chinese medicine preparation can comprise a traditional Chinese medicine composition capable of treating the skin rash and pharmaceutically acceptable auxiliary materials, and the traditional Chinese medicine composition is prepared from the following traditional Chinese medicine materials in parts by weight: 30-50 parts of honeysuckle, 30-50 parts of purslane, 30-50 parts of radix sophorae flavescentis, 30-50 parts of cortex dictamni, 20-40 parts of radix scutellariae, 20-40 parts of lithospermum, 20-40 parts of radix sileris, 10-20 parts of dried alum, 20-40 parts of bletilla striata and 20-50 parts of radix sanguisorbae.

Further, the auxiliary materials are medicinal auxiliary materials which have enhanced curative effects on the main medicines.

Further, the preparation of the traditional Chinese medicine composition can be patches, cataplasm, ointment, plaster, gel, liniment, lotion, film coating agent and the like.

In one embodiment, the formulation of the traditional Chinese medicine composition is selected from lotions.

In a third aspect, the present invention provides an application of the Chinese medicinal composition according to the first aspect in preparing a preparation for treating rash, wherein the rash is mainly caused by insufficient endowment of a patient, invasion of wind, heat and dampness evil, and special toxin of a sensitive medicament.

The medicine properties and effects of the traditional Chinese medicinal materials are as follows:

Honeysuckle flower: sweet in flavor, cold in nature, enters lung, heart and stomach meridians, and clears away heat and toxic materials, and dispels wind-heat. Can be used for treating carbuncle, furuncle, pharyngitis, erysipelas, dysentery with blood, wind-heat type common cold, and epidemic febrile disease.

Purslane: sour taste, cold nature, liver and large intestine meridians, heat and toxic materials clearing away, blood cooling and hemostasis, dysentery stopping. Can be used for treating dysentery with heat toxin, carbuncle, furuncle, eczema, erysipelas, snake and insect bite, hematochezia, hemorrhoid, metrorrhagia, and hemorrhage.

Radix Sophorae Flavescentis: bitter taste, cold nature, heart, liver, stomach, large intestine and bladder meridian, heat-clearing and dampness-eliminating, insecticidal and diuretic. Can be used for treating dysentery, hematochezia, jaundice, uroschesis, leucorrhea with reddish discharge, pudendum swelling, pruritus vulvae, eczema, skin pruritus, and scabies; it is used for treating trichomonas vaginitis.

Radix Scutellariae Baicalensis: bitter taste, cold property, lung, gallbladder, spleen, large intestine and small intestine channels, heat clearing, dampness eliminating, fire purging, toxin removing, hemostasis and miscarriage prevention. Can be used for treating damp-heat, summer-heat, chest distress, emesis, damp-heat distention and fullness, dysentery, jaundice, cough due to lung heat, polydipsia due to high fever, hematemesis, epistaxis, carbuncle, swelling, sore, and fetal movement.

Radix Arnebiae: sweet and salty in flavor, cold in nature, good in property of inducing heart and liver meridians, clearing heat and cooling blood, promoting blood circulation and removing toxicity, promoting eruption and removing spots. Can be used for treating excessive heat and toxic materials, macula, purple black, measles, skin infection, eczema, and scald due to fire and water.

Radix Sanguisorbae: bitter, sour and astringent taste, slightly cold nature, good liver and large intestine meridians, blood cooling and hemostasis, detoxification and sore healing. Can be used for treating hematochezia, hemorrhoid, bloody dysentery, metrorrhagia, scald due to fire and water, carbuncle, and skin sore.

Cortex Dictamni Radicis: bitter taste, cold nature, spleen, stomach and bladder meridians entered, heat-clearing and dampness-drying, wind-dispelling and detoxifying. Can be used for treating sore due to damp-heat, yellow Shui Linli, eczema, rubella, scabies, arthralgia due to wind-damp-heat, jaundice, and dark urine.

Wind prevention: pungent and sweet in flavor, slightly warm in nature, enter bladder, liver and spleen meridians, dispel wind, relieve exterior syndrome, dispel dampness, alleviate pain and stop spasm. Can be used for treating common cold, headache, rheumatalgia, rubella, pruritus, and tetanus.

Drying alum: sour and astringent taste, cold nature, and good property of inducing menstruation in lung, spleen, liver and large intestine, astringing dampness and healing sore, stopping bleeding and resolving putrefaction. Can be used for treating eczema, wet sore, rectocele, hemorrhoid, purulent ear, pudendum itch, leukorrhagia, epistaxis, and epistaxis polyp meat.

Bletilla striata: bitter, sweet and astringent in flavor, slightly cold in nature. It can be used for treating pulmonary, hepatic and gastric menstruation, astringing, stopping bleeding, relieving swelling, and promoting granulation. Can be used for treating hemoptysis, hematemesis, traumatic hemorrhage, pyocutaneous disease, toxic swelling, and chapped skin.

The invention takes dittany bark and kuh-seng as principal drugs to remove dampness and heat, and aims at the root of the disease, and is matched with baikal skullcap root, honeysuckle, purslane, garden burnet root and lithospermum to clear away heat and toxic materials and cool blood, and strengthens the function of the principal drugs to remove dampness, and the divaricate saposhnikovia root, dried alum and bletilla tuber are matched with principal drugs to play roles of dispelling wind and relieving itching, astringing dampness and healing sore and improving symptoms.

Drawings

Figure 140 patients were graded for rash before and after treatment.

Detailed Description

The following describes the invention in more detail. The description of these embodiments is provided to assist understanding of the present invention, but is not intended to limit the present invention. In addition, the technical features of the embodiments described below may be combined with each other as long as they do not collide with each other.

The experimental methods in the following examples, unless otherwise specified, are conventional, and the experimental materials used in the following examples, unless otherwise specified, are commercially available.

Example 1

Study object: patients with bronchogenic carcinoma and also with EGFRIs medications, with signs of skin erosion, exudation, hypertrophy and lichenification were diagnosed.

The diagnosis of lung cancer is based on: lung cancer diagnostic criteria: refer to WHO chest tumor classification (fifth edition): 2021; chinese clinical oncology society, diagnosis and treatment guide for non-small cell lung cancer 2023, people health Press 2023.

EGFRIs diagnostic criteria for rash associated with: 1. the patient receives EGFRIs treatments; 2. rash appears after administration; 3. rashes appear as acneiform or pustular and are distributed in the areas of sebaceous gland hyperactivity with itching.

Diagnostic criteria for traditional Chinese medicine: EGFRIs traditional Chinese medicine diagnostic criteria for related rashes: wind-heat type: acne-like rash is accompanied by itching, reddish complexion, reddish eyes, pale red or red tongue. Damp-heat type: pustular rash with bitter taste, yellow urine, red tongue and yellow coating.

Condition of selection:

Grading of EGFRIs-related rash and EGFRIs-related rash after diagnosis of bronchopulmonary carcinoma and EGFRIs drug treatment employs a grade standard of EGFRIs-related adverse skin reaction MASCC established by the national institute of cancer support therapy (multinational association ofsupportive CARE IN CANCER, MASCC).

Exclusion conditions:

1. complicated with other skin diseases, allergic patients to traditional Chinese medicines used in the project, and the treatment of EGFRIs and the grading of skin rash MASCC are carried out in 1 grade.

2. The severity of adverse skin reactions is below grade 4 according to the common adverse reaction event evaluation criteria (CTCAE) version 5.0 established by the U.S. department of health and public service, national institutes of health, and national cancer institute.

The research method comprises the following steps:

The invention relates to a traditional Chinese medicine lotion formula:

30 parts of honeysuckle, 30 parts of purslane, 30 parts of radix sophorae flavescentis, 20 parts of radix scutellariae, 20 parts of lithospermum, 20 parts of radix sanguisorbae, 30 parts of cortex dictamni, 20 parts of radix saposhnikoviae, 10 parts of dried alum and 20 parts of bletilla striata.

The application method of the traditional Chinese medicine lotion comprises the following steps: the traditional Chinese medicine is decocted with 1000 ml of water for 30 minutes, the traditional Chinese medicine liquid is reserved with 500 ml, the non-woven fabric is soaked in the medicine liquid and then is externally applied to the skin erosion, hypertrophy and lichenification, if the rash is sporadic or is not suitable for external application locally, the medicine liquid can be directly applied to the rash, if the area of the rash is wide, the medicine amount can be properly increased, and a medicine bath mode is adopted for increasing the medicine liquid. After use, the medicine is washed with clean water for 30 minutes twice a day to avoid pigmentation caused by the residue of the Chinese medicine liquid, and is continuously applied for 14 days.

Observation follow-up: when the patient is in the group, the patient is subjected to detailed inquiry and physical examination, and the original medical record is recorded. Rashes of patients enrolled were graded according to MASCC criteria. Patients were followed on day 7 and day 14 of the group, and rashes were re-graded according to MASCC criteria.

The main observation indexes are as follows:

Changes in rash grading before and after treatment: grading of EGFRIs-related rash the EGFRIs-related adverse skin reaction MASCC grading criteria established by the cancer support therapy multinational institute (multinational association ofsupportive CARE IN CANCER, MASCC) are used, see table 1.

TABLE 1EGFRIs related rash grading criteria

Note that: the distance between rashes is more than or equal to 2cm, which is 2 points

Secondary observations: referring to the guidelines of clinical research on new traditional Chinese medicines, the quantitative scoring changes of the symptoms of the wet sore of the traditional Chinese medicine before and after treatment. Total score = itching degree score + rash face score + rash morphology score, see table 2.

TABLE 2 quantitative Table of skin adverse reaction symptoms

Note that: 1 the rash scores add up if polymorphic lesions. 2 skin area burn palmar measurement: each palm area is a scoring unit, and less than one palm area is calculated in half of the scoring unit. The area of skin lesions was calculated using the PASI scoring system.

Curative effect judgment criteria:

EGFRIs is effective in treating moderate and severe rash. Patient efficacy is evaluated according to efficacy evaluation criteria established by the American EGFRIs related skin toxicity seminar consensus, and efficacy is divided into three categories, healing, improvement and invalidation.

And (3) healing: namely, the skin adverse reaction of the patient to be evaluated disappears, no subjective symptoms and no infection symptoms are caused, and the life and work can be normally carried out.

Improvement: namely, the rated skin adverse reaction of the patient is reduced by one stage or more, or the skin adverse reaction distribution of the patient is changed into local form widely, subjective symptoms of the patient are reduced or eliminated, and the quality of life score of the patient is obviously improved earlier.

Invalidation: the skin adverse reaction of the patient is evaluated to be unchanged compared with the skin adverse reaction before treatment, or the skin adverse reaction grading is improved, or the skin adverse reaction distribution of the patient is changed from local to systemic distribution, the patient has new subjective symptoms or the original subjective symptoms are aggravated, and the life quality of the patient is obviously deteriorated.

Total effective rate of treatment: i.e. the post-treatment efficacy is evaluated as the sum of the number of cases of recovery and improvement, accounting for the percentage of the total number of cases of the group, i.e. total effective rate = (recovery + improvement)/total number of cases x100%.

Symptom quantification data scoring criteria: and calculating the treatment efficiency according to the quantitative scoring change of the skin damage pruritus degree, distribution and morphology. Therapeutic efficiency calculation formula (nimodipine method): [ (pre-treatment score-post-treatment score)/pre-treatment score ] ×100%.

And (3) healing: the skin damage is completely resolved, the local symptoms disappear, and the score is reduced by more than or equal to 95% before and after treatment;

the effect is shown: most of skin damage is resolved, local symptoms are obviously improved, and scores are reduced by less than 95% before and after treatment by 70%;

The method is effective: partial skin damage is resolved, local symptoms are improved, and scores are reduced by less than 70% before and after treatment;

invalidation: there is no improvement or increase in skin lesions, no improvement or aggravation of local symptoms, and a decrease in score of < 30% before and after treatment.

Study results:

a total of 40 lung adenocarcinoma patients in the group, wherein 16 men and 24 women; average age 63.2 years (+ -11.6 years), total use EGFRIs drugs (including gefitinib, erlotinib, icotinib, almitinib, octenib, afatinib, dacatinib) for all patients. All patients are given 2 weeks of external treatment with traditional Chinese medicines, and the treatment effects are as follows:

The total effective rate of the drug is 77.5% in the evaluation of the therapeutic effect of the consensus standard of the American EGFRIs related skin toxicity workshop, 7 cases of recovery, 24 cases of improvement and 9 cases of ineffectiveness. The grading of rash of patients before and after treatment is shown in FIG. 1.

Evaluation of efficacy of symptom quantification data scoring criteria: 9 cases are cured, 4 cases are obvious, 24 cases are effective, 3 cases are ineffective, and the total effective rate is 92.5%. The mean value of the pre-treatment symptom scores is 6.23 (+ -1.72), the mean value of the post-treatment scores is 2.45 (+ -1.76), the average symptom improvement rate is 60.7%, the symptom scores of the patients before and after treatment are shown in table 3, and the curative effect data of different skin lesions are shown in table 4.

TABLE 3 distribution of patient symptom scores before and after treatment

TABLE 4 therapeutic efficacy data for different skin lesions types

In the process of analyzing the clinical treatment effect of the prescription, the prescription is found to have more prominent treatment effect on the rash which is characterized by erosion and exudation. And (3) data display: the local rash is manifested by 13 patients suffering from erosion exudation or even suppuration, the score is reduced by 5.08 minutes before and after treatment, the exudation and the erosion wound are all improved or even eliminated, and the pain is also obviously improved. The average score reduction before and after treatment of the other 27 cases was 3.15, and the two had statistical differences (P < 0.05), indicating that the composition had better treatment effect on exudation and erosion-based skin changes than acne skin changes manifested as a single papule or pustule.

The literature reports that the effective rate of treating the skin rash related to EGFRs is 55.56% by adopting a Western medicine treatment scheme (EGFRIs related clinical practice guidelines for skin toxicity: the external hydrocortisone cream for patients with moderate rash is orally taken simultaneously with minocycline, and the external hydrocortisone cream for patients with severe rash is orally taken in combination with minocycline.

The external treatment of the traditional Chinese medicine lotion has good clinical curative effect. No obvious adverse reaction occurs in the external treatment process of the traditional Chinese medicine of all patients, and only two patients react the odor of the medicine to be bad.

Typical cases:

typical case 1: men, 35 years old, 2023, 3 months and 21 days visit, patients diagnosed with lung adenocarcinoma, lymph node metastasis, bone metastasis, pericardium metastasis, double lung metastasis, EGFR 19-DEL, failure of first line targeted drug therapy, small cell transformation after second line anti-vascular immunotherapy, double lung cancer lymphangitis after 2-cycle CE regimen chemotherapy, mediastinum and cervical lymph node radiotherapy. When the dacatinib is taken for treatment, dense rash of the head and the face occurs after 2 weeks of administration, suppurative folliculitis is accompanied, meanwhile, a plurality of rash of the trunk part is classified as 2 minutes, and after the lotion (prepared in example 1) is adopted for external treatment for 2 weeks, the rash classification is reduced to 2 minutes. Although the rash area is not obviously reduced, the skin redness, swelling and suppuration are obviously improved, the color is darkened, partial desquamation is realized, and the symptoms of itching and pain are obviously improved.

Typical case 2: men, 53 years old, 7 months and 19 days 2022 visit, patients diagnose lung adenocarcinoma, double lung and pleural metastasis in 2021 month, and the condition is stable by using the oxtinib treatment. The skin rash on the chest and back was evident in the treatment, with itching discomfort, the skin rash was evaluated and graded for 3 minutes, the skin rash was significantly reduced, the symptoms were substantially disappeared, and the skin rash was graded for 1 minute after 2 weeks of external application treatment with the lotion of the present invention (prepared in example 1).

Typical case 3: women, 75 years old, 25 days of treatment in 2023, 4 months, patients diagnosed with left lung adenocarcinoma for 1 year, lung portal lymph node metastasis, double lung metastasis, brain metastasis, 45m copies of dactyltinib were treated once daily until now, the disease was stable, the symptoms were seen as scattered throughout the body with itching, the skin rash was classified as 3 minutes with the front chest and back, after 2 weeks of bathing with the lotion of the present invention (prepared in example 1), the symptoms disappeared, and the skin rash was evaluated as healing.

Claims

1. The traditional Chinese medicine composition for treating EGFRIs related rashes is characterized by being prepared from the following traditional Chinese medicinal materials in parts by weight: 30-50 parts of honeysuckle, 30-50 parts of purslane, 30-50 parts of radix sophorae flavescentis, 30-50 parts of cortex dictamni, 20-40 parts of radix scutellariae, 20-40 parts of lithospermum, 20-40 parts of radix sileris, 10-20 parts of dried alum, 20-40 parts of bletilla striata and 20-50 parts of radix sanguisorbae.

2. The traditional Chinese medicine composition for treating EGFRIs-related rash according to claim 1, wherein the traditional Chinese medicine composition is prepared from the following traditional Chinese medicinal materials in parts by weight: 40 parts of honeysuckle, 40 parts of purslane, 40 parts of radix sophorae flavescentis, 40 parts of cortex dictamni, 30 parts of radix scutellariae, 30 parts of lithospermum, 30 parts of radix saposhnikoviae, 15 parts of dried alum, 30 parts of bletilla striata and 40 parts of radix sanguisorbae.

3. A Chinese medicinal composition preparation for treating EGFRIs related rash, which is characterized by comprising the Chinese medicinal composition according to claim 1 or 2 and pharmaceutically acceptable auxiliary materials.

4. The traditional Chinese medicine composition preparation for treating EGFRIs-related rash according to claim 3, wherein the traditional Chinese medicine composition preparation is one of a patch, a cataplasm, an ointment, a plaster, a gel, a liniment, a lotion and a film coating agent.

5. The traditional Chinese medicine composition preparation for treating EGFRIs-related rash according to claim 3, wherein the preparation of the traditional Chinese medicine composition is a lotion.

6. Use of a traditional Chinese medicine composition according to any one of claims 1-2 for the preparation of a medicament for the treatment of EGFRIs-related rashes.